Sun Pharma's brand, Brevipil (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg was launched in the market on Day-1 post patent expiry of innovator product (21 February 2021).
Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.
Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
Powered by Capital Market - Live News